Early Post-operative Stimulated Serum Thyroglobulin : Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer
AIM: The aims of the study are to evaluate the predictive value of early post-operative stimulated thyroglobulin (sTg) analysis on the recurrence risk, and to define a cut-off value that is related to recurrence risk in low to intermediate risk papillary thyroid cancer (PTC).
METHODS: This retrospective cohort study included individuals who were diagnosed with PTC aged 18 years or older and had been operated by experienced surgeons of a tertiary university hospital between the years 2011 and 2021. The American Thyroid Association thyroid cancer guidelines version 2015 was used as the risk stratification system. Early sTg measurement obtained at 3-4 weeks after surgery when TSH >30 µIU/mL. Data was collected from the hospital database. A total of 328 patients who had post-operative early sTg values with negative anti-Tg antibodies were included.
RESULTS: The median age was 44 years. Of the 328 patients, 223 (68%) were women. The median tumor diameter was 11 mm. One hundred ninety-one patients (58.2%) had low risk and 137 (41.8%) had intermediate risk for recurrent disease. Of the 328 patients, 4.0% had recurrent disease. In multivariate Cox regression, post-operative early sTg value [OR: 1.070 (1.038-1.116), P = .000], and the pre-operative malign cytology [OR: 1.483 (1.080-2.245), P = .042] were independent risk factors for recurrence. On the ROC curve analysis, the cut-off value of early sTg was 4.1 ng/mL for those with recurrent disease.
CONCLUSION: This study demonstrated that early sTg could predict recurrent disease in patients with low to intermediate risk PTC. A cut-off of 4.1 ng/mL was identified with a high negative predictive value.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
The American surgeon - 89(2023), 12 vom: 06. Dez., Seite 5996-6004 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sezer, Havva [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9010-34-8 |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 08.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/00031348231157816 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358113067 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358113067 | ||
| 003 | DE-627 | ||
| 005 | 20240114231911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/00031348231157816 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM358113067 | ||
| 035 | |a (NLM)37309609 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sezer, Havva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early Post-operative Stimulated Serum Thyroglobulin |b Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: The aims of the study are to evaluate the predictive value of early post-operative stimulated thyroglobulin (sTg) analysis on the recurrence risk, and to define a cut-off value that is related to recurrence risk in low to intermediate risk papillary thyroid cancer (PTC) | ||
| 520 | |a METHODS: This retrospective cohort study included individuals who were diagnosed with PTC aged 18 years or older and had been operated by experienced surgeons of a tertiary university hospital between the years 2011 and 2021. The American Thyroid Association thyroid cancer guidelines version 2015 was used as the risk stratification system. Early sTg measurement obtained at 3-4 weeks after surgery when TSH >30 µIU/mL. Data was collected from the hospital database. A total of 328 patients who had post-operative early sTg values with negative anti-Tg antibodies were included | ||
| 520 | |a RESULTS: The median age was 44 years. Of the 328 patients, 223 (68%) were women. The median tumor diameter was 11 mm. One hundred ninety-one patients (58.2%) had low risk and 137 (41.8%) had intermediate risk for recurrent disease. Of the 328 patients, 4.0% had recurrent disease. In multivariate Cox regression, post-operative early sTg value [OR: 1.070 (1.038-1.116), P = .000], and the pre-operative malign cytology [OR: 1.483 (1.080-2.245), P = .042] were independent risk factors for recurrence. On the ROC curve analysis, the cut-off value of early sTg was 4.1 ng/mL for those with recurrent disease | ||
| 520 | |a CONCLUSION: This study demonstrated that early sTg could predict recurrent disease in patients with low to intermediate risk PTC. A cut-off of 4.1 ng/mL was identified with a high negative predictive value | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a early stimulated thyroglobulin | |
| 650 | 4 | |a intermediate-risk | |
| 650 | 4 | |a low-risk | |
| 650 | 4 | |a papillary thyroid cancer | |
| 650 | 4 | |a recurrence | |
| 650 | 7 | |a Thyroglobulin |2 NLM | |
| 650 | 7 | |a 9010-34-8 |2 NLM | |
| 650 | 7 | |a Iodine Radioisotopes |2 NLM | |
| 700 | 1 | |a Yazıcı, Dilek |e verfasserin |4 aut | |
| 700 | 1 | |a Terzioğlu, Tarık |e verfasserin |4 aut | |
| 700 | 1 | |a Tezelman, Serdar |e verfasserin |4 aut | |
| 700 | 1 | |a Canbaz, Hande Bulut |e verfasserin |4 aut | |
| 700 | 1 | |a Yerlikaya, Aslıhan |e verfasserin |4 aut | |
| 700 | 1 | |a Demirkol, Mehmet Onur |e verfasserin |4 aut | |
| 700 | 1 | |a Kapran, Yersu |e verfasserin |4 aut | |
| 700 | 1 | |a Çolakoğlu, Bülent |e verfasserin |4 aut | |
| 700 | 1 | |a Çilingiroğlu, Eda Nur |e verfasserin |4 aut | |
| 700 | 1 | |a Alagöl, Faruk |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American surgeon |d 1951 |g 89(2023), 12 vom: 06. Dez., Seite 5996-6004 |w (DE-627)NLM000046418 |x 1555-9823 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2023 |g number:12 |g day:06 |g month:12 |g pages:5996-6004 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/00031348231157816 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2023 |e 12 |b 06 |c 12 |h 5996-6004 | ||